



(43) International Publication Date
8 September 2017 (08.09.2017)

(51) International Patent Classification:

C07D 235/30 (2006.01) C07D 403/04 (2006.01)
C07D 401/04 (2006.01)

(21) International Application Number:

PCT/US2016/033841

(22) International Filing Date:

23 May 2016 (23.05.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/302,781 2 March 2016 (02.03.2016) US

(71) Applicant: **TD2 INC.** [US/US]; 13208 E. Shea Blvd., Suite 100, Scottsdale, Arizona 85259 (US).

(72) Inventors: **WANG, Tong**; 13208 E. Shea Blvd., Suite 100, Scottsdale, Arizona 85259 (US). **GATELY, Stephen**; 13208 E. Shea Blvd., Suite 100, Scottsdale, Arizona 85259 (US).

(74) Agent: **FULLER, Rodney J.**; Booth Udall Fuller, PLC, 1255 W. Rio Salado Pkwy., Suite 215, Tempe, Arizona 85281 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: AMINOBENZIMIDAZOLE DERIVATIVES



(57) Abstract: The present invention is directed to aminobenzimidazole derivative compounds and compositions comprising thereof. The present invention also relates to uses of these compounds to treat or prevent several conditions including neoplasia, dysplasia, metaplasia, and cancer.

WO 2017/151165 A1

AMINOBENZIMIDAZOLE DERIVATIVES

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Patent Application No. 62/302,781,
 5 filed March 2, 2016, the contents of which are incorporated herein by reference in their entirety.

BACKGROUND OF THE INVENTION

Cancer is the second leading cause of death in the United States and despite new
 breakthroughs that have led to decreased mortality, many cancers remain refractory to treatment.
 10 In addition, many cancers often develop resistance to current chemotherapies over time. The
 typical treatments such as chemotherapy, radiotherapy and surgery also cause a broad spectrum
 of undesirable side effects. Clearly the field is in significant need of novel compounds and
 methods of slowing the expansion of cancer cells and that are useful in the treatment of cancer.

15 SUMMARY OF THE INVENTION

The present invention provides among other things a compound that is effective in the
 treatment of cancer.

It is an object of the invention to provide a pharmaceutical composition that slows the
 expansion of cancer cells.

20 It is an object of the invention to treat various forms of cancer.

The above and other objects may be achieved using devices involving a compound of
 formula (I):



wherein:

the group denoted by X is selected from the group consisting of: H, halo, -C₁-C₆ alkyl,
 25 aryl, -C₃-C₇ cycloalkyl, and -3- to 10-membered heterocycle, any of which may be unsubstituted
 or substituted with one or more of the following: -halo, -C₁-C₆ alkyl, -O-(C₁-C₆ alkyl), -OH, -


CN, -COOR', -OC(O)R', NHR', N(R')₂, -NHC(O)R' or -C(O)NHR' groups wherein R' may be -H or -C₁-C₆ alkyl;

the group denoted by A is selected from the group consisting of: a bond, -C₁-C₆ alkyl, or -C₃-C₇ cycloalkyl, any of which may be unsubstituted or substituted with one or more of the following: -halo, -C₁-C₆ alkyl, -O-(C₁-C₆ alkyl), -OH, -CN, -COOR', -OC(O)R', NHR', N(R')₂, -NHC(O)R' or -C(O)NHR' groups wherein R' may be -H or -C₁-C₆ alkyl;

the group denoted by Y is selected from the group consisting of: H, -C₁-C₆ alkyl, -C₃-C₇ cycloalkyl, aryl or -3-to 10-membered heterocycle, any of which may be unsubstituted or substituted with one or more of the following: -halo, -C₁-C₆ alkyl, -O-(C₁-C₆ alkyl), -OH, -CN, -COOR', -OC(O)R', NHR', N(R')₂, -NHC(O)R' or -C(O)NHR' groups wherein R' may be -H or -C₁-C₆ alkyl; and

the group denoted by Q is selected from the group consisting of: -halo, -C₁-C₆ alkyl, -O-(C₁-C₆ alkyl), -OH, -CN, -COOR', -OC(O)R', NHR', N(R')₂, -NHC(O)R' or -C(O)NHR' groups wherein R' may be -H or -C₁-C₆ alkyl.

In another embodiment, the present invention relates to a compound of formula (II):



wherein:

the group denoted by X is selected from the group consisting of: H, halo, -C₁-C₆ alkyl, aryl, -C₃-C₇ cycloalkyl, and -3-to 10-membered heterocycle, any of which may be unsubstituted or substituted with one or more of the following: -halo, -C₁-C₆ alkyl, -O-(C₁-C₆ alkyl), -OH, -CN, -COOR', -OC(O)R', NHR', N(R')₂, -NHC(O)R' or -C(O)NHR' groups wherein R' may be -H or -C₁-C₆ alkyl;

the group denoted by A is selected from the group consisting of: -C₁-C₆ alkyl, or -C₃-C₇ cycloalkyl, any of which may be unsubstituted or substituted with one or more of the following: -halo, -C₁-C₆ alkyl, -O-(C₁-C₆ alkyl), -C₃-C₁₂ cycloalkyl, 3 to 10-membered heterocycle, aryl, -OH, -CN, -COOR', -OC(O)R', NHR', N(R')₂, -NHC(O)R' or -C(O)NHR' groups wherein R' may be -H or -C₁-C₆ alkyl; and

the group denoted by Q is selected from the group consisting of: -halo, -C₁-C₆ alkyl, -O-(C₁-C₆ alkyl), -OH, -CN, -COOR', -OC(O)R', NHR', N(R')₂, -NHC(O)R' or -C(O)NHR' groups wherein R' may be -H or -C₁-C₆ alkyl.

5 The above and other objects may be achieved using methods involving slowing the growth of tumors with an effective amount of a pharmaceutical composition that includes the disclosed compound and, in some aspects of the invention, one or more pharmaceutically acceptable carriers.

10 The above and other objects may be achieved by methods involving treating a mammal with an effective amount of a pharmaceutical composition that includes the disclosed compound and, in some aspects of the invention, one or more pharmaceutically acceptable carriers.

15 Aspects and applications of the invention presented here are described in the drawings and detailed description of the invention. Unless specifically noted, it is intended that the words and phrases in the specification and the claims be given their plain, ordinary, and accustomed meaning to those of ordinary skill in the applicable arts. Inventors are fully aware that they can be their own lexicographers if desired

20 Inventors are also aware of the normal precepts of English grammar. Thus, if a noun, term, or phrase is intended to be further characterized, specified, or narrowed in some way, then such noun, term, or phrase will expressly include additional adjectives, descriptive terms, or other modifiers in accordance with the normal precepts of English grammar. Absent the use of such adjectives, descriptive terms, or modifiers, it is the intent that the noun, term, or phrase is given its broadest possible meaning.

25 Further, the inventors are fully informed of the standards and application of the special provisions of 35 U.S.C. § 112, ¶ 6. Thus, the use of the words “function,” “means” or “step” in the Detailed Description or Description of the Drawings or claims is not intended to somehow indicate a desire to invoke the special provisions of 35 U.S.C. § 112, ¶ 6, to define the invention. To the contrary, if the provisions of 35 U.S.C. § 112, ¶ 6 are sought to be invoked to define the inventions, the claims will specifically and expressly state the exact phrases “means for” or “step for, and will also recite the word “function” (i.e., will state “means for performing the function of [insert function]”), without also reciting in such phrases any structure, material or act in support
30 of the function. Thus, even when the claims recite a “means for performing the function of . . . “ or “step for performing the function of . . . ,” if the claims also recite any structure, material or

acts in support of that means or step, or that perform the recited function, then it is the clear intention of the inventors not to invoke the provisions of 35 U.S.C. § 112, ¶ 6. Moreover, even if the provisions of 35 U.S.C. § 112, ¶ 6 are invoked to define the claimed inventions, it is intended that the inventions not be limited only to the specific structure, material or acts that are described
5 in the preferred embodiments, but in addition, include any and all structures, materials or acts that perform the claimed function as described in alternative embodiments or forms of the invention, or that are well known present or later-developed, equivalent structures, material or acts for performing the claimed function.

10 BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 depicts the effect of treatment with Compound ID#1, Compound ID#2, or Compound ID#3 on tumor volume in a human myeloma tumor xenograft model.

FIG. 2 depicts the effect of treatment with Compound ID#1, Compound ID#2, or Compound ID#3 in combination with dexamethasone and pomalidomide on tumor volume in a
15 human myeloma tumor xenograft model.


DETAILED DESCRIPTION OF THE INVENTION

In the following description, and for the purposes of explanation, numerous specific details are set forth in order to provide a thorough understanding of the various aspects of the invention. It will be understood, however, by those skilled in the relevant arts, that the present
20 invention may be practiced without these specific details. In other instances, known structures and devices are shown or discussed more generally in order to avoid obscuring the invention. In many cases, a description of the operation is sufficient to enable one to implement the various forms of the invention. It should be noted that there are many different and alternative
25 configurations, devices, compositions, and technologies to which the disclosed invention may be applied. The full scope of the inventions is not limited to the examples that are described below.

Herein the inventors disclose a compound of formula (I):



and a compound of formula (II):



The group denoted by X may be any of H, halo, -C₁-C₆ alkyl, aryl, -C₃-C₇ cycloalkyl or -3-to 10-membered heterocycle, any of which may be unsubstituted or substituted with one or more of the following: -halo, -C₁-C₆ alkyl, -O-(C₁-C₆ alkyl), -OH, -CN, -COOR', -OC(O)R', NHR', N(R')₂, -NHC(O)R' or -C(O)NHR' groups wherein R' may be -H or -C₁-C₆ alkyl.

The groups denoted by A may be any of a bond, -C₁-C₆ alkyl, or -C₃-C₇ cycloalkyl, any of which may be unsubstituted or substituted with one or more of the following: -halo, -C₁-C₆ alkyl, -O-(C₁-C₆ alkyl), -OH, -CN, -COOR', -OC(O)R', NHR', N(R')₂, -NHC(O)R' or -C(O)NHR' groups wherein R' may be -H or -C₁-C₆ alkyl.

The group denoted by Y may be any of H, -C₁-C₆ alkyl, -C₃-C₇ cycloalkyl, aryl or -3-to 10-membered heterocycle any of which may be unsubstituted or substituted with one or more of the following: -halo, -C₁-C₆ alkyl, -O-(C₁-C₆ alkyl), -OH, -CN, -COOR', -OC(O)R', NHR', N(R')₂, -NHC(O)R' or -C(O)NHR' groups wherein R' may be -H or -C₁-C₆ alkyl.

The group denoted by Q may be H, -halo, -C₁-C₆ alkyl, -O-(C₁-C₆ alkyl), -OH, -CN, -COOR', -OC(O)R', NHR', N(R')₂, -NHC(O)R' or -C(O)NHR' groups wherein R' may be -H or -C₁-C₆ alkyl.

A -C₁-C₆ alkyl group includes any straight or branched, saturated or unsaturated, substituted or unsubstituted hydrocarbon comprised of between one and six carbon atoms. Examples of -C₁-C₆ alkyl groups include, but are not limited to methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, neohexyl, ethylenyl, propylenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 2-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, acetylenyl, pentynyl, 1-butylnyl, 2-butylnyl, 1-pentylnyl, 2-pentylnyl, 1-hexynyl, 2-hexynyl and 3-hexynyl groups. Substituted -C₁-C₆ alkyl groups may include any applicable chemical moieties. Examples of groups that may be substituted onto any of the above listed -C₁-C₆ alkyl groups include but are not limited to the following examples: halo, -C₁-C₆ alkyl, -O-(C₁-C₆ alkyl), -OH, -CN, -COOR', -OC(O)R', -NHR', N(R')₂, -NHC(O)R' or -C(O)NHR' groups. The groups denoted R' above may be -H or any -C₁-C₆ alkyl.

An aryl group includes any unsubstituted or substituted phenyl or naphthyl group. Examples of groups that may be substituted onto any aryl group include, but are not limited to: halo, -C₁-C₆ alkyl, -O-(C₁-C₆ alkyl), -OH, -CN, -COOR', -OC(O)R', NHR', N(R')₂, -NHC(O), R', or -C(O)NEtR'. The group denoted R' may be -H or any -C₁-C₆ alkyl.

5 A C₃-C₇ cycloalkyl group includes any 3-, 4-, 5-, 6-, or 7-membered substituted or unsubstituted non-aromatic carbocyclic ring. Examples of C₃-C₇ cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentadienyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptanyl, 1,3-cyclohexadienyl, -1, 4- cyclohexadienyl, -1, 3- cycloheptadienyl, and -1,3, 5-cycloheptatrienyl groups. Examples of groups that may be substituted onto C₃-C₇ cycloalkyl groups include, but are not limited to: -halo, -C₁-C₆ alkyl, -O-
10 (C₁-C₆ alkyl), -OH, -CN, -COOR', -OC(O) R', NHR', N(R')₂, -NHC(O)R' or -C(O)NHR' groups. The groups denoted R' above include an -H or any unsubstituted -C₁-C₆ alkyl, examples of which are listed above.

Halo groups include any halogen. Examples include but are not limited to -F, -Cl, -Br, or
15 -I.


A heterocycle may be any optionally substituted saturated, unsaturated or aromatic cyclic moiety wherein said cyclic moiety is interrupted by at least one heteroatom selected from oxygen (O), sulfur (S) or nitrogen (N). Heterocycles may be monocyclic or polycyclic rings. For example, suitable substituents include halogen, halogenated -C₁-C₆ alkyl, halogenated -C₁-C₆
20 alkoxy, amino, amidino, amido, azido, cyano, guanidino, hydroxyl, nitro, nitroso, urea, OS(O)₂R; OS(O)₂OR, S(O)₂OR S(O)₀₋₂R, C(O)OR wherein R may be H, C₁-C₆ alkyl, aryl or 3 to 10 membered heterocycle) OP(O)OR₁OR₂, P(O)OR₁OR₂, SO₂NR₁R₂, NR₁SO₂R₂ C(R₁)NR₂ C(R₁)NOR₂, R₁ and R₂ may be independently H, C₁-C₆ alkyl, aryl or 3 to 10 membered heterocycle), NR₁C(O)R₂, NR₁C(O)OR₂, NR₃C(O)NR₂R₁, C(O)NR₁R₂, OC(O)NR₁R₂. For these
25 groups, R₁, R₂ and R₃ are each independently selected from H, C₁-C₆ alkyl, aryl or 3 to 10 membered heterocycle or R₁ and R₂ are taken together with the atoms to which they are attached to form a 3 to 10 membered heterocycle.

Possible substituents of heterocycle groups include halogen (Br, Cl, I or F), cyano, nitro, oxo, amino, C₁₋₄ alkyl (e.g., CH₃, C₂H₅, isopropyl), C₁₋₄ alkoxy (e.g., OCH₃, OC₂H₅),
30 halogenated C₁₋₄ alkyl (e.g., CF₃, CHF₂), halogenated C₁₋₄ alkoxy (e.g., OCF₃, OC₂F₅), COOH,

COO-C₁₋₄ alkyl, CO-C₁₋₄ alkyl, C₁₋₄ alkyl -S- (e.g., CH₃S, C₂H₅S), halogenated C₁₋₄ alkyl -S- (e.g., CF₃S, C₂F₅S), benzyloxy, and pyrazolyl.

Examples of heterocycles include but are not limited to azepinyl, aziridinyl, azetyl, azetidiny, diazepinyl, dithiadiazinyl, dioxazepinyl, dioxolanyl, dithiazolyl, furanyl, isooxazolyl, isothiazolyl, imidazolyl, morpholinyl, morpholino, oxetanyl, oxadiazolyl, oxiranyl, oxazinyl, oxazolyl, piperazinyl, pyrazinyl, pyridazinyl, pyrimidinyl, piperidyl, piperidino, pyridyl, pyranyl, pyrazolyl, pyrrolyl, pyrrolidinyl, thiatiazolyl, tetrazolyl, thiadiazolyl, triazolyl, thiazolyl, thienyl, tetrazinyl, thiadiazinyl, triazinyl, thiazinyl, thiopyranyl furoisoxazolyl, imidazothiazolyl, thienoisothiazolyl, thienothiazolyl, imidazopyrazolyl, cyclopentapyrazolyl, pyrrolopyrrolyl, thienothienyl, thiadiazolopyrimidinyl, thiazolothiazinyl, thiazolopyrimidinyl, thiazolopyridinyl, oxazolopyrimidinyl, oxazolopyridyl, benzoxazolyl, benzisothiazolyl, benzothiazolyl, imidazopyrazinyl, purinyl, pyrazolopyrimidinyl, imidazopyridinyl, benzimidazolyl, indazolyl, benzoxathioly, benzodioxolyl, benzodithioly, indoliziny, indoliny, isoindoliny, furopyrimidinyl, furopyridyl, benzofuranyl, isobenzofuranyl, thienopyrimidinyl, thienopyridyl, benzothienyl, cyclopentaoxazinyl, cyclopentafuranyl, benzoxazinyl, benzothiazinyl, quinazoliny, naphthyridinyl, quinoliny, isoquinoliny, benzopyranyl, pyridopyridazinyl, and pyridopyrimidinyl groups.

The disclosed compound and its intermediates may exist in different tautomeric forms. Tautomers include any structural isomers of different energies that have a low energy barrier to interconversion. One example is proton tautomers (prototropic tautomers). In this example, the interconversions occur via the migration of a proton. Examples of prototropic tautomers include but are not limited to keto-enol and imine-enamine isomerizations. In another example illustrated graphically below, proton migration between the 1-position and 3-position nitrogen atoms of the benzimidazole ring may occur. As a result, Formulas Ia and Ib are tautomeric forms of each other:



The invention further encompasses any other physiochemical or stereochemical form that the disclosed compound may assume. Such forms include diastereomers, racemates, isolated enantiomers, hydrated forms, solvated forms, or any other known or yet to be disclosed

crystalline, polymorphic crystalline, or amorphous form. Amorphous forms lack a distinguishable crystal lattice and therefore lack an orderly arrangement of structural units. Many pharmaceutical compounds have amorphous forms. Methods of generating such chemical forms will be well known by one with skill in the art.

5 In some aspects of the invention the disclosed compound is in the form of a pharmaceutically acceptable salt. Pharmaceutically acceptable salts include any salt derived from an organic or inorganic acid. Examples of such salts include but are not limited to the following: salts of hydrobromic acid, hydrochloric acid, nitric acid, phosphoric acid and sulphuric acid. Organic acid addition salts include, for example, salts of acetic acid, benzenesulphonic acid, 10 benzoic acid, camphorsulphonic acid, citric acid, 2-(4-chlorophenoxy)-2-methylpropionic acid, 1, 2-ethanedisulphonic acid, ethanesulphonic acid, ethylenediaminetetraacetic acid (EDTA), fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, N-glycolylarsanilic acid, 4-hexylresorcinol, hippuric acid, 2-(4-hydroxybenzoyl) benzoic acid, 1-hydroxy-2-naphthoic acid, 3-hydroxy-2-naphthoic acid, 2-hydroxyethanesulphonic acid, lactobionic acid, n-dodecyl 15 sulphuric acid, maleic acid, malic acid, mandelic acid, methanesulphonic acid, methyl sulphuric acid, mucic acid, 2-naphthalenesulphonic acid, pamoic acid, pantothenic acid, phosphanilic acid ((4-aminophenyl) phosphonic acid), picric acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, terephthalic acid, p-toluenesulphonic acid, 10-undecenoic acid or any other such acid now known or yet to be disclosed. It will be appreciated by one skilled in the art that 20 such pharmaceutically acceptable salts may be used in the formulation of a pharmacological composition. Such salts may be prepared by reacting the disclosed compound with a suitable acid in a manner known by those skilled in the art.

The invention further encompasses aspects in which a protecting group is added to the compound. One skilled in the art would recognize that during the synthesis of complex 25 molecules, one group on the disclosed compound may happen to interfere with an intended reaction that includes a second group on the compound. Temporarily masking or protecting the first group encourages the desired reaction. Protection involves introducing a protecting group to a group to be protected, carrying out the desired reaction, and removing the protecting group. Removal of the protecting group may be referred to as deprotection. Examples of compounds to 30 be protected in some syntheses include hydroxy groups, amine groups, carbonyl groups, carboxyl groups and thiols.

Many protective groups and reagents capable of introducing them into synthetic processes have been and are continuing to be developed today. A protecting group may result from any chemical synthesis that selectively attaches a group that is resistant to certain reagents to the chemical group to be protected without significant effects on any other chemical groups in the molecule, remains stable throughout the synthesis, and may be removed through conditions that do not adversely react with the protected group, nor any other chemical group in the molecule. Multiple protecting groups may be added throughout a synthesis and one skilled in the art would be able to develop a strategy for specific addition and removal of the protecting groups to and from the groups to be protected.

Protecting groups, reagents that add those groups, preparations of those reagents, protection and deprotection strategies under a variety of conditions, including complex syntheses with mutually complementary protecting groups are all well known in the art. Nonlimiting examples of all of these may be found in Green et al, *Protective Groups in Organic Chemistry* 2nd Ed., (Wiley 1991), and Harrison et al, *Compendium of Synthetic Organic Methods*, Vols. 1-8 (Wiley, 1971-1996) both of which hereby incorporated by reference in its entirety.

Racemates, individual enantiomers, or diastereomers of the disclosed compound may be prepared by specific synthesis or resolution through any method now known or yet to be disclosed. For example, the disclosed compound may be resolved into its enantiomers by the formation of diastereomeric pairs through salt formation using an optically active acid. Enantiomers are fractionally crystallized and the free base regenerated. In another example, enantiomers may be separated by chromatography. Such chromatography may be any appropriate method now known or yet to be disclosed that is appropriate to separate enantiomers such as HPLC on a chiral column.

The invention further encompasses pharmaceutical compositions that include one of the disclosed compounds as an ingredient. Such pharmaceutical compositions may take any physical form necessary depending on a number of factors including the desired method of administration and the physicochemical and stereochemical form taken by the disclosed compound or pharmaceutically acceptable salts of the compound. Such physical forms include a solid, liquid, gas, sol, gel, aerosol, or any other physical form now known or yet to be disclosed. The concept of a pharmaceutical composition including the disclosed compound also encompasses the disclosed compound or a pharmaceutically acceptable salt thereof without any other additive.

The physical form of the invention may affect the route of administration and one skilled in the art would know to choose a route of administration that takes into consideration both the physical form of the compound and the disorder to be treated. Pharmaceutical compositions that include one of the disclosed compounds may be prepared using methodology well known in the pharmaceutical art. A pharmaceutical composition that includes one of the disclosed compounds may include a second effective compound of a distinct chemical formula from the disclosed compound. This second effective compound may have the same or a similar molecular target as the target or it may act upstream or downstream of the molecular target of the disclosed compound with regard to one or more biochemical pathways.

Pharmaceutical compositions including one of the disclosed compounds include materials capable of modifying the physical form of a dosage unit. In one nonlimiting example, the composition includes a material that forms a coating that holds in the compound. Materials that may be used in such a coating include, for example, sugar, shellac, gelatin, or any other inert coating agent.

Pharmaceutical compositions including one of the disclosed compounds may be prepared as a gas or aerosol. Aerosols encompass a variety of systems including colloids and pressurized packages. Delivery of a composition in this form may include propulsion of a pharmaceutical composition including the disclosed compound through use of liquefied gas or other compressed gas or by a suitable pump system. Aerosols may be delivered in single-phase, bi-phasic, or tri-phasic systems.

In some aspects of the invention, the pharmaceutical composition one of the disclosed compounds is in the form of a solvate. Such solvates are produced by the dissolution of the disclosed compound in a pharmaceutically acceptable solvent. Pharmaceutically acceptable solvents include any mixtures of more than one solvent. Such solvents may include pyridine, chloroform, propan-1-ol, ethyl oleate, ethyl lactate, ethylene oxide, water, ethanol, and any other solvent that delivers a sufficient quantity of the disclosed compound to treat the affliction without serious complications arising from the use of the solvent in a majority of patients.

Pharmaceutical compositions that include one of the disclosed compounds may also include a pharmaceutically acceptable carrier. Carriers include any substance that may be administered with the disclosed compound with the intended purpose of facilitating, assisting, or helping the administration or other delivery of the compound. Carriers include any liquid, solid,

semisolid, gel, aerosol or anything else that may be combined with the disclosed compound to aid in its administration. Examples include diluents, adjuvants, excipients, water, oils (including petroleum, animal, vegetable, or synthetic oils). Such carriers include particulates such as a tablet or powder, liquids such as an oral syrup or injectable liquid and inhalable aerosols. Further
5 examples include saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, and urea. Such carriers may further include binders such as ethyl cellulose, carboxymethylcellulose, microcrystalline cellulose, or gelatin; excipients such as starch, lactose or dextrans; disintegrating agents such as alginic acid, sodium alginate, Primogel, and corn starch; lubricants such as magnesium stearate or Sterotex; glidants such as colloidal silicon dioxide; sweetening agents
10 such as sucrose or saccharin, a flavoring agent such as peppermint, methyl salicylate or orange flavoring, or coloring agents. Further examples of carriers include polyethylene glycol, cyclodextrin, oils, or any other similar liquid carrier that may be formulated into a capsule. Still further examples of carriers include sterile diluents such as water for injection, saline solution, physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils such as synthetic
15 mono or diglycerides, polyethylene glycols, glycerin, cyclodextrin, propylene glycol or other solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose, thickening agents, lubricating agents, and coloring agents.

20 The pharmaceutical composition including one of the disclosed compounds may take any of a number of formulations depending on the physicochemical form of the composition and the type of administration. Such forms include solutions, suspensions, emulsions, tablets, pills, pellets, capsules, capsules including liquids, powders, sustained-release formulations, directed release formulations, lyophilates, suppositories, emulsions, aerosols, sprays, granules, powders,
25 syrups, elixirs, or any other formulation now known or yet to be disclosed. Additional examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E. W. Martin, hereby incorporated by reference in its entirety.

Methods of administration include, but are not limited to, oral administration and parenteral administration. Parenteral administration includes, but is not limited to intradermal,
30 intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, sublingual, intramucosal, intracerebral, intraventricular, intrathecal, intravaginal, transdermal, rectal, by

inhalation, or topically to the ears, nose, eyes, or skin. Other methods of administration include but are not limited to infusion techniques including infusion or bolus injection, by absorption through epithelial or mucocutaneous linings such as oral mucosa, rectal and intestinal mucosa. Compositions for parenteral administration may be enclosed in ampoule, a disposable syringe or
5 a multiple-dose vial made of glass, plastic or other material.

Administration may be systemic or local. Local administration is administration of the disclosed compound to the area in need of treatment. Examples include local infusion during surgery, topical application, local injection, or administration by a catheter, by a suppository, or by an implant. Administration may be by direct injection at the site (or former site) of a cancer,
10 tumor, or precancerous tissue or into the central nervous system by any suitable route, including intraventricular and intrathecal injection. Intraventricular injection can be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration may be achieved by any of a number of methods known in the art. Examples include use of an inhaler or nebulizer, formulation with an aerosolizing agent, or via
15 perfusion in a fluorocarbon or synthetic pulmonary surfactant. The disclosed compound may be delivered in the context of a vesicle such as a liposome or any other natural or synthetic vesicle.

A pharmaceutical composition formulated so as to be administered by injection may be prepared by dissolving the disclosed compound with water so as to form a solution. In addition, a surfactant may be added to facilitate the formation of a homogeneous solution or suspension.
20 Surfactants include any complex capable of non-covalent interaction with the disclosed compound so as to facilitate dissolution or homogeneous suspension of the compound.

Pharmaceutical compositions including one of the disclosed compounds may be prepared in a form that facilitates topical or transdermal administration. Such preparations may be in the form of a solution, emulsion, ointment, gel base, transdermal patch or iontophoresis device.
25 Examples of bases used in such compositions include petrolatum, lanolin, polyethylene glycols, beeswax, mineral oil, diluents such as water and alcohol, and emulsifiers and stabilizers, thickening agents, or any other suitable base now known or yet to be disclosed.

Cancer cells include any cells derived from a tumor, neoplasm, cancer, precancer, cell line, or any other source of cells that are ultimately capable of potentially unlimited expansion
30 and growth. Cancer cells may be derived from naturally occurring sources or may be artificially created. Cancer cells may also be capable of invasion into other tissues and metastasis when

placed into an animal host. Cancer cells further encompass any malignant cells that have invaded other tissues and/or metastasized. One or more cancer cells in the context of an organism may also be called a cancer, tumor, neoplasm, growth, malignancy, or any other term used in the art to describe cells in a cancerous state.

5 Expansion of a cancer cell includes any process that results in an increase in the number of individual cells derived from a cancer cell. Expansion of a cancer cell may result from mitotic division, proliferation, or any other form of expansion of a cancer cell, whether *in vitro* or *in vivo*. Expansion of a cancer cell further encompasses invasion and metastasis. A cancer cell may be in physical proximity to cancer cells from the same clone or from different clones that may or
10 may not be genetically identical to it. Such aggregations may take the form of a colony, tumor or metastasis, any of which may occur *in vivo* or *in vitro*. Slowing the expansion of the cancer cell may be brought about either by inhibiting cellular processes that promote expansion or by bringing about cellular processes that inhibit expansion. Processes that inhibit expansion include processes that slow mitotic division and processes that promote cell senescence or cell death.
15 Examples of specific processes that inhibit expansion include caspase dependent and independent pathways, autophagy, necrosis, apoptosis, and mitochondrial dependent and independent processes and further include any such processes yet to be disclosed.

 Addition of a pharmaceutical composition to cancer cells includes all actions by which an effect of the pharmaceutical composition on the cancer cell is realized. The type of addition
20 chosen will depend upon whether the cancer cells are *in vivo*, *ex vivo*, or *in vitro*, the physical or chemical properties of the pharmaceutical composition, and the effect the composition is to have on the cancer cell. Nonlimiting examples of addition include addition of a solution including the pharmaceutical composition to tissue culture media in which *in vitro* cancer cells are growing; any method by which a pharmaceutical composition may be administered to an animal including
25 intravenous, per os, parenteral, or any other of the methods of administration; or the activation or inhibition of cells that in turn have effects on the cancer cells such as immune cells (e.g. macrophages and CD8⁺ T cells) or endothelial cells that may differentiate into blood vessel structures in the process of angiogenesis or vasculogenesis.

 Determination of an effective amount of the disclosed compound is within the capability
30 of those skilled in the art, especially in light of the detailed disclosure provided herein. The effective amount of a pharmaceutical composition used to effect a particular purpose as well as

its toxicity, excretion, and overall tolerance may be determined in cell cultures or experimental animals by pharmaceutical and toxicological procedures either known now by those skilled in the art or by any similar method yet to be disclosed. One example is the determination of the IC₅₀ (half maximal inhibitory concentration) of the pharmaceutical composition in vitro in cell lines
5 or target molecules. Another example is the determination of the LD₅₀ (lethal dose causing death in 50 % of the tested animals) of the pharmaceutical composition in experimental animals. The exact techniques used in determining an effective amount will depend on factors such as the type and physical/chemical properties of the pharmaceutical composition, the property being tested, and whether the test is to be performed in vitro or in vivo. The determination of an effective
10 amount of a pharmaceutical composition will be well known to one of skill in the art who will use data obtained from any tests in making that determination. Determination of an effective amount of disclosed compound for addition to a cancer cell also includes the determination of an effective therapeutic amount, including the formulation of an effective dose range for use in vivo, including in humans.

15 Treatment is contemplated in living entities including but not limited to mammals (particularly humans) as well as other mammals of economic or social importance, including those of an endangered status. Further examples include livestock or other animals generally bred for human consumption and domesticated companion animals.

The toxicity and therapeutic efficacy of a pharmaceutical composition may be determined
20 by standard pharmaceutical procedures in cell cultures or animals. Examples include the determination of the IC₅₀ (the half maximal inhibitory concentration) and the LD₅₀ (lethal dose causing death in 50% of the tested animals) for a subject compound. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage may vary depending upon the dosage form employed and the route of
25 administration utilized.

The effective amount of one of the disclosed compounds to result in the slowing of expansion of the cancer cells would preferably result in a concentration at or near the target tissue that is effective in slowing cellular expansion in neoplastic cells but have minimal effects on non-neoplastic cells, including non-neoplastic cells exposed to radiation or recognized
30 chemotherapeutic chemical agents. Concentrations that produce these effects can be determined

using, for example, apoptosis markers such as the apoptotic index and/or caspase activities either *in vitro* or *in vivo*.

Treatment of a condition is the practice of any method, process, or procedure with the intent of halting, inhibiting, slowing or reversing the progression of a disease, disorder or condition, substantially ameliorating clinical symptoms of a disease disorder or condition, or substantially preventing the appearance of clinical symptoms of a disease, disorder or condition, up to and including returning the diseased entity to its condition prior to the development of the disease.

The addition of a therapeutically effective amount of one of the disclosed compounds encompasses any method of dosing of a compound. Dosing of the disclosed compound may include single or multiple administrations of any of a number of pharmaceutical compositions that include the disclosed compound as an active ingredient. Examples include a single administration of a slow release composition, a course of treatment involving several treatments on a regular or irregular basis, multiple administrations for a period of time until a diminution of the disease state is achieved, preventative treatments applied prior to the instigation of symptoms, or any other dosing regimen known in the art or yet to be disclosed that one skilled in the art would recognize as a potentially effective regimen. A final dosing regimen including the regularity of and mode of administration will be dependent on any of a number of factors including but not limited to the subject being treated; the severity of the affliction; the manner of administration, the stage of disease development, the presence of one or more other conditions such as pregnancy, infancy, or the presence of one or more additional diseases; or any other factor now known or yet to be disclosed that affects the choice of the mode of administration, the dose to be administered and the time period over which the dose is administered.

Pharmaceutical compositions that include one of the disclosed compounds may be administered prior to, concurrently with, or after administration of a second pharmaceutical composition that may or may not include the compound. If the compositions are administered concurrently, they are administered within one minute of each other. If not administered concurrently, the second pharmaceutical composition may be administered a period of one or more minutes, hours, days, weeks, or months before or after the pharmaceutical composition that includes the compound. Alternatively, a combination of pharmaceutical compositions may be cyclically administered. Cycling therapy involves the administration of one or more

pharmaceutical compositions for a period of time, followed by the administration of one or more different pharmaceutical compositions for a period of time and repeating this sequential administration, in order to reduce the development of resistance to one or more of the compositions, to avoid or reduce the side effects of one or more of the compositions, and/or to improve the efficacy of the treatment.

The invention further encompasses kits that facilitate the administration of one of the disclosed compounds to a diseased entity. An example of such a kit includes one or more unit dosages of the compound. The unit dosage would be enclosed in a preferably sterile container and would be comprised of the disclosed compound and a pharmaceutically acceptable carrier. In another aspect, the unit dosage would comprise one or more lyophilates of the compound. In this aspect of the invention, the kit may include another preferably sterile container enclosing a solution capable of dissolving the lyophilate. However, such a solution need not be included in the kit and may be obtained separately from the lyophilate. In another aspect, the kit may include one or more devices used in administering the unit dosages or a pharmaceutical composition to be used in combination with the compound. Examples of such devices include, but are not limited to, a syringe, a drip bag, a patch or an enema. In some aspects of the invention, the device comprises the container that encloses the unit dosage.

Pharmaceutical compositions including one of the disclosed compounds may be used in methods of treating cancer. Such methods involve the administration of a therapeutic amount of a pharmaceutical composition that includes the disclosed compound and/or a pharmaceutically acceptable salt thereof to a mammal, preferably a mammal in which a cancer has been diagnosed.

A therapeutic amount further includes the prevention of progression of the cancer to a neoplastic, malignant or metastatic state. Such preventative use is indicated in conditions known or suspected of preceding progression to neoplasia or cancer, in particular, where non-neoplastic cell growth consisting of hyperplasia, metaplasia, or most particularly, dysplasia has occurred (for review of such abnormal growth conditions, see Robbins and Angell, 1976, *Basic Pathology*, 2d Ed., W. B. Saunders Co., Philadelphia, pp. 68-79). Hyperplasia is a form of controlled cell proliferation involving an increase in cell number in a tissue or organ, without significant alteration in structure or activity. For example, endometrial hyperplasia often precedes endometrial cancer and precancerous colon polyps often transform into cancerous

lesions. Metaplasia is a form of controlled cell growth in which one type of adult or fully differentiated cell substitutes for another type of adult cell. Metaplasia can occur in epithelial or connective tissue cells. A typical metaplasia involves a somewhat disorderly metaplastic epithelium. Dysplasia is frequently a forerunner of cancer, and is found mainly in the epithelia; it is the most disorderly form of non-neoplastic cell growth, involving a loss in individual cell uniformity and in the architectural orientation of cells. Dysplastic cells often have abnormally large, deeply stained nuclei, and exhibit pleomorphism. Dysplasia characteristically occurs where there exists chronic irritation or inflammation, and is often found in the cervix, respiratory passages, oral cavity, and gall bladder.

Alternatively or in addition to the presence of abnormal cell growth characterized as hyperplasia, metaplasia, or dysplasia, the presence of one or more characteristics of a transformed phenotype or of a malignant phenotype, displayed in vivo or displayed in vitro by a cell sample derived from a patient can indicate the desirability of prophylactic/therapeutic administration of the pharmaceutical composition that includes the compound. Such characteristics of a transformed phenotype include morphology changes, looser substratum attachment, loss of contact inhibition, loss of anchorage dependence, protease release, increased sugar transport, decreased serum requirement, expression of fetal antigens, disappearance of the 250,000 dalton cell surface protein, etc. (see also id., at pp. 84-90 for characteristics associated with a transformed or malignant phenotype). Further examples include leukoplakia (a benign-appearing hyperplastic or dysplastic lesion of the epithelium) or Bowen's disease (a carcinoma in situ), which are pre-neoplastic lesions indicating the desirability of prophylactic intervention. In another example, fibrocystic disease, including cystic hyperplasia, mammary dysplasia, adenosis, or benign epithelial hyperplasia, indicates the desirability of prophylactic intervention.

In some aspects of the invention, use of the disclosed compound may be determined by one or more physical factors such as tumor size and grade or one or more molecular markers and/or expression signatures that indicate prognosis and the likely response to treatment with the compound. For example, determination of estrogen (ER) and progesterone (PR) steroid hormone receptor status has become a routine procedure in assessment of breast cancer patients. See, for example, Fitzgibbons et al, *Arch. Pathol. Lab. Med.* 124:966-78, 2000. Tumors that are hormone receptor positive are more likely to respond to hormone therapy and also typically grow less aggressively, thereby resulting in a better prognosis for patients with ER⁺/PR⁺ tumors. In a

further example, overexpression of human epidermal growth factor receptor 2 (HER-2/neu), a transmembrane tyrosine kinase receptor protein, has been correlated with poor breast cancer prognosis (see, e.g., Ross et al, *The Oncologist* 8:307-25, 2003), and Her-2 expression levels in breast tumors are used to predict response to the anti-Her-2 monoclonal antibody therapeutic
5 trastuzumab (Herceptin®, Genentech, South San Francisco, CA).

In another aspect of the invention, the diseased entity exhibits one or more predisposing factors for malignancy that may be treated by administration of a pharmaceutical composition including the compound. Such predisposing factors include but are not limited to chromosomal translocations associated with a malignancy such as the Philadelphia chromosome for chronic
10 myelogenous leukemia and t(14;18) for follicular lymphoma; an incidence of polyposis or Gardner's syndrome that are indicative of colon cancer; benign monoclonal gammopathy which is indicative of multiple myeloma; kinship with persons who have had or currently have a cancer or precancerous disease; exposure to carcinogens; or any other predisposing factor that indicates in increased incidence of cancer now known or yet to be disclosed.

The invention further encompasses methods of treating cancer that comprise combination
15 therapies, wherein the combination therapies comprise the administration of a pharmaceutical composition including one of the disclosed compounds and another treatment modality. Such treatment modalities include, but are not limited to, radiotherapy, chemotherapy, surgery, immunotherapy, cancer vaccines, radioimmunotherapy, treatment with pharmaceutical
20 compositions other than those which include the disclosed compound, or any other method that effectively treats cancer in combination with the disclosed compound now known or yet to be disclosed. Combination therapies may act synergistically. That is, the combination of the two therapies is more effective than either therapy administered alone. This results in a situation in which lower dosages of both treatment modalities may be used effectively. This in turn reduces
25 the toxicity and side effects, if any, associated with the administration either modality without a reduction in efficacy.

In another aspect of the invention, the pharmaceutical composition including one of the disclosed compounds is administered in combination with a therapeutically effective amount of radiotherapy. Radiotherapy may be administered concurrently with, prior to, or following the
30 administration of the pharmaceutical composition including the compound. Radiotherapy may act additively or synergistically with the pharmaceutical composition including the compound.

This particular aspect of the invention would be most effective in cancers known to be responsive to radiotherapy. Cancers known to be responsive to radiotherapy include, but are not limited to, Non-Hodgkin's lymphoma, Hodgkin's disease, Ewing's sarcoma, testicular cancer, prostate cancer, ovarian cancer, bladder cancer, larynx cancer, cervical cancer, nasopharynx cancer, breast cancer, colon cancer, pancreatic cancer, head and neck cancer, esophageal cancer, 5 rectal cancer, small-cell lung cancer, non-small cell lung cancer, brain tumors, other CNS neoplasms, or any other such tumor now known or yet to be disclosed.

Examples of pharmaceutical compositions that may be used in combination with one of the disclosed compounds include nucleic acid binding compositions, such as cis-10 diamminedichloro platinum (II) (cisplatin), doxorubicin, 5-fluorouracil, taxol, and topoisomerase inhibitors such as etoposide, teniposide, irinotecan, and topotecan. Still other pharmaceutical compositions include antiemetic compositions, such as metoclopramide, domperidone, prochlorperazine, promethazine, chlorpromazine, trimethobenzamide, ondansetron, granisetron, hydroxyzine, acetylleucine monoethanolamine, alizapride, azasetron, benzquinamide, 15 bietanautine, bromopride, buclizine, clebopride, cyclizine, dimenhydrinate, diphenidol, dolasetron, meclizine, methallatal, metopimazine, nabilone, oxyperndyl, pipamazine, scopolamine, sulpiride, tetrahydrocannabinols, thiethylperazine, thioproperazine, and tropisetron.

Still other examples of pharmaceutical compositions that may be used in combination with the pharmaceutical composition including one of the disclosed compounds are 20 hematopoietic colony stimulating factors. Examples of hematopoietic colony stimulating factors include, but are not limited to, filgrastim, sargramostim, molgramostim, and epoietin alfa. Alternatively, the pharmaceutical composition including one of the disclosed compounds may be used in combination with an anxiolytic agent. Examples of anxiolytic agents include, but are not limited to, buspirone, and benzodiazepines such as diazepam, lorazepam, oxazepam, 25 chlorazepate, clonazepam, chlordiazepoxide and alprazolam.

Pharmaceutical compositions that may be used in combination with pharmaceutical compositions that include one of the disclosed compounds may include analgesic agents. Such agents may be opioid or non-opioid analgesic. Non-limiting examples of opioid analgesics include morphine, heroin, hydromorphone, hydrocodone, oxymorphone, oxycodone, metopon, 30 apomorphine, normorphine, etorphine, buprenorphine, meperidine, lopermide, anileridine, ethoheptazine, piminidine, betaprodine, diphenoxylate, fentanil, sufentanil, alfentanil,

remifentanil, levorphanol, dextromethorphan, phenazocine, pentazocine, cyclazocine, methadone, isomethadone, and propoxyphene. Suitable non-opioid analgesic agents include, but are not limited to, aspirin, celecoxib, rofecoxib, diclofinac, diflusal, etodolac, fenoprofen, flurbiprofen, ibuprofen, ketoprofen, indomethacin, ketorolac, meclofenamate, mefanamic acid, nabumetone, naproxen, piroxicam, sulindac, or any other analgesic now known or yet to be disclosed.

In other aspects of the invention, pharmaceutical compositions including one of the disclosed compounds may be used in combination with a method that involves treatment of cancer *ex vivo*. One example of such a treatment is an autologous stem cell transplant. In this method, a diseased entity's autologous hematopoietic stem cells are harvested and purged of all cancer cells. A therapeutic amount of a pharmaceutical composition including one of the disclosed compounds may then be administered to the patient prior to restoring the entity's bone marrow by addition of either the patient's own or donor stem cells.

Cancers that may be treated by pharmaceutical compositions including the one of the disclosed compounds either alone or in combination with another treatment modality include solid tumors such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangi endotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon cancer, colorectal cancer, kidney cancer, pancreatic cancer, bone cancer, breast cancer, ovarian cancer, prostate cancer, esophageal cancer, stomach cancer, oral cancer, nasal cancer, throat cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms'tumor, cervical cancer, uterine cancer, testicular cancer, small cell lung carcinoma, bladder carcinoma, lung cancer, epithelial carcinoma, glioma, glioblastoma multiforme, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, skin cancer, melanoma, neuroblastoma, and retinoblastoma.

Additional cancers that may be treated by pharmaceutical compositions including the disclosed compound include blood borne cancers such as acute lymphoblastic leukemia

(“ALL”), acute lymphoblastic B-cell leukemia, acute lymphoblastic T-cell leukemia, acute myeloblastic leukemia (“AML”), acute promyelocytic leukemia (“APL”), acute monoblastic leukemia, acute erythroleukemic leukemia, acute megakaryoblastic leukemia, acute myelomonocytic leukemia, acute nonlymphocytic leukemia, acute undifferentiated leukemia,
5 chronic myelocytic leukemia (“CML”), chronic lymphocytic leukemia (“CLL”), hairy cell leukemia, multiple myeloma, lymphoblastic leukemia, myelogenous leukemia, lymphocytic leukemia, myelocytic leukemia, Hodgkin's disease, non-Hodgkin's Lymphoma, Waldenstrom's macroglobulinemia, Heavy chain disease, and Polycythemia vera.


Examples that represent different aspects of the invention follow. Such examples should
10 not be construed as limiting the scope of the disclosure. Alternative mechanistic pathways and analogous structures within the scope of the invention would be apparent to those skilled in the art.

EXAMPLES


Elements and acts in the example are intended to illustrate the invention for the sake of
15 simplicity and have not necessarily been rendered according to any particular sequence or embodiment. The example is also intended to establish possession of the invention by the Inventors.

Example 1. Example compounds of formula (I) or formula (II)



20 4-((1-(cyclohexylmethyl)-1H-benzo[d]imidazol-2-yl)amino)-N-hydroxybenzamide. ID# 1




4-((1-cyclohexyl-1H-benzo[d]imidazol-2-yl)amino)-N-hydroxybenzamide. ID# 2




4-((1-cycloheptyl-1H-benzo[d]imidazol-2-yl)amino)-N-hydroxybenzamide. ID# 3

4-((1-((1-fluorocyclohexyl)methyl)-1H-benzo[d]imidazol-2-yl)amino)-N-hydroxybenzamide.
ID# 4


4-((1-(cyclopentylmethyl)-1H-benzo[d]imidazol-2-yl)amino)-N-hydroxybenzamide. ID# 5




4-((1-(2-cyclopentylethyl)-1H-benzo[d]imidazol-2-yl)amino)-N-hydroxybenzamide. ID# 6




4-((1-((4,4-difluorocyclohexyl)methyl)-1H-benzo[d]imidazol-2-yl)amino)-N-hydroxybenzamide
ID# 7




4-((1-((4,4-difluorocyclohexyl)methyl)-5-fluoro-1H-benzo[d]imidazol-2-yl)amino)-N-hydroxybenzamide. ID# 8



N-hydroxy-4-((1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-benzo[d]imidazol-2-yl)amino)benzamide. ID# 9



4-((5-fluoro-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-benzo[d]imidazol-2-yl)amino)-N-hydroxybenzamide. ID# 10



5 Example 2. Cell Viability Assays with MM1.S cells

Cell viability in the presence of varying concentrations of the above listed compounds at different time points was used to assess cytotoxicity and the effect of the compounds on cell proliferation. IC₅₀ (or percent activity) data for the disclosed compounds in the MM1.S cell line are summarized in Table 1.

10 **Cell Viability Assay** – Cell viability was measured by the CellTiter -GLO[®] cell viability assay from Promega (Madison, WI). The CellTiter -GLO[®] Luminescent Cell Viability Assay is a homogeneous method to determine the number of viable cells in culture based on quantitation of the ATP present, which signals the presence of metabolically active cells. Following treatment, CellTiter -GLO[®] is added to treatment wells and incubated at 37° C. luminescence values were
15 measured at using a Molecular Devices Spectramax microplate reader

Single Agent Studies – Cells were grown to 70% confluency, trypsinized, counted, and seeded in 96 well flat-bottom plates at a final concentration of 2.5x10³-5x10³ cells/well (Day 0). Cells were allowed to incubate in growth media for 24 hours. Treatment with the test agents or standard agents began on Day 1 and continued for 72 hours. At the 72 hour timepoint, treatment
20 containing media was removed. Viable cell numbers are quantified by the CellTiter-GLO[®] cell viability assay as described above. Results from these studies were used to calculate an IC₅₀ value (concentration of drug that inhibits cell growth by 50 percent of control) for each compound.

Data Collection – For single agent and combination studies, data from each experiment
25 was collected and expressed as % Cell Growth using the following calculation:

$$\% \text{ Cell Growth} = (f_{\text{test}}/f_{\text{vehicle}}) \times 100$$

Where f_{test} is the fluorescence of the tested sample, and f_{vehicle} is the fluorescence of the vehicle in which the drug is dissolved. Dose response graphs and IC_{50} values were generated using Prism 6 software (GraphPad) using the following equation:

$$Y = \frac{\text{Top-Bottom}}{1 + 10^{((\log IC_{50} - X) \cdot \text{HillSlope})}}$$

Where X is the logarithm of concentration and Y is the response. Y starts at the Bottom and goes to Top with a sigmoid shape.

Table 1. IC_{50} of example compounds in MM1.S cells

| Compound ID# | IC_{50} in MM1.S (μM) |
|--------------|--------------------------------------|
| 1 | 0.5 |
| 2 | 2.0 |
| 3 | 2.1 |
| 4 | 2.6 |
| 5 | 2.2 |
| 6 | 1.1 |
| 7 | 0.7 |
| 8 | 1.2 |
| 9 | 2.9 |
| 10 | 2.9 |

Example 3. Cell Viability Assays with Various Cell Lines

Compound ID#1 (a compound of formula (I)) and Compound ID#3 (a compound of formula (II)) were tested for the inhibition of cancer cell proliferation. Cell viability in the presence of varying concentrations of Compound ID#1 and Compound ID#3 at different time points was used to assess cytotoxicity and the effect of the compounds on cell proliferation. The 50% inhibitory concentration (IC_{50}) data for the compounds is summarized in Table 2. The data clearly show the surprising and unexpected increased anti-cancer activity associated with Compound ID#1 compared to Compound ID#3.

Cell Viability Assay – Cell viability was measured by the CellTiter-Glo® cell viability assay Promega (Madison, Wis.). The CellTiter-Glo® Luminescent Cell Viability Assay is a

Table 2

| Tumor Type | Cell line | ID#1 IC ₅₀ (uM) | ID#3 IC ₅₀ (uM) | Fold Improvement ID#1 over ID#3 | Percent Improvement ID#1 over ID#3 |
|------------|-----------|----------------------------|----------------------------|---------------------------------|------------------------------------|
| GBM | U251 | 1.58 | 4.07 | 2.58 | 61.18% |
| Breast | MDA-157 | 2.75 | 7.59 | 2.76 | 63.77% |
| Breast | MDA468 | 3.86 | 9.33 | 2.42 | 58.63% |
| Breast | MCF7 | 1.96 | 3.55 | 1.81 | 44.79% |
| GIST | GIST48 | 1.32 | 4.24 | 3.21 | 68.87% |
| GIST | GIST882 | 5.75 | 17.78 | 3.09 | 67.66% |
| Uterine | AN3CA | 1.60 | 4.57 | 2.86 | 64.99% |
| Uterine | MFE280 | 5.01 | 9.71 | 1.94 | 48.40% |
| Uterine | SKUT-1 | 3.80 | 9.55 | 2.51 | 60.21% |
| Uterine | SKUT-1B | 2.51 | 6.92 | 2.76 | 63.73% |
| Uterine | MFE296 | 4.37 | 12.59 | 2.88 | 65.29% |
| Uterine | Ishikawa | 1.70 | 4.37 | 2.57 | 61.10% |
| Uterine | SNG-M | 1.70 | 8.07 | 4.75 | 78.93% |
| Myeloma | H929 | 0.83 | 1.38 | 1.66 | 39.86% |
| Myeloma | MM1.S | 0.50 | 2.09 | 4.18 | 76.08% |
| Myeloma | KMS-11 | 1.42 | 3.02 | 2.13 | 52.98% |
| Myeloma | KMS-34 | 0.61 | 1.36 | 2.23 | 55.15% |
| Myeloma | RPMI-8226 | 0.66 | 1.51 | 2.29 | 56.29% |

| Tumor Type | Cell line | ID#1 IC₅₀ (uM) | ID#3 IC₅₀ (uM) | Fold Improvement ID#1 over ID#3 | Percent Improvement ID#1 over ID#3 |
|-------------------|------------------|----------------------------------|----------------------------------|--|---|
| Myeloma | U266 | 1.17 | 4.1 | 3.50 | 71.46% |
| ALL | RS4-11 | 1.10 | 2.44 | 2.22 | 54.92% |
| AML | MV411 | 0.63 | 2.75 | 4.37 | 77.09% |
| CML | K562 | 1.58 | 5.25 | 3.32 | 69.90% |
| Lymphoma | SUDHL-4 | 0.24 | 4.17 | 17.38 | 94.24% |
| Lymphoma | SUDHL-10 | 0.55 | 1.51 | 2.75 | 63.58% |
| Lymphoma | OCI-LY3 | 1.05 | 2.29 | 2.18 | 54.15% |
| Lymphoma | RAMOS | 1.38 | 2.88 | 2.09 | 52.08% |
| Lymphoma | Raji | 1.83 | 4.83 | 2.64 | 62.11% |
| Lymphoma | Mino | 1.20 | 4.17 | 3.48 | 71.22% |
| Lymphoma | BC-1 | 1.79 | 4.93 | 2.75 | 63.69% |
| Lymphoma | JEKO | 0.97 | 2.22 | 2.29 | 56.31% |
| Lymphoma | Toledo | 0.81 | 3.21 | 3.96 | 74.77% |
| NSCLC | A549 | 2.29 | 10 | 4.37 | 77.10% |
| NSCLC | H1650 | 6.61 | 18.2 | 2.75 | 63.68% |
| NSCLC | H460 | 3.47 | 10.47 | 3.02 | 66.86% |
| NSCLC | H1437 | 2.19 | 4.79 | 2.19 | 54.28% |
| Ovarian | ES2 | 3.98 | 13.18 | 3.31 | 69.80% |
| Ovarian | A2780 | 2.03 | 5.58 | 2.75 | 63.62% |

Example 4. In Vivo Screening in a model of Human Myeloma1. *Single Agent Screening*

In vivo efficacy studies of Compound ID #1, Compound ID #2, and Compound ID #3 were tested in human MM1.S xenograft model as shown in **FIG. 1**. Female athymic nude mice were inoculated with 5.0×10^6 MM1.S human myeloma cells suspended in a mixture of 50% Matrigel and 50% tissue culture media in a total volume of 100 μ L. Eighteen days following inoculation, the mice were pair-matched into four groups of five mice per group at an average tumor volume of 171 mm^3 per group. Group 1 (G1) was treated with vehicle only daily for 19 days. Group 2 (G2) was treated with Compound ID #1 at 100 mg/kg daily for 19 days. Group 3 (G3) was treated with Compound ID #2 at 100 mg/kg daily for 19 days. Group 4 (G4) was treated with Compound ID #3 at 100 mg/kg daily for 19 days. Vehicle and Compound ID #1, Compound ID #2 and Compound ID #3 were administered orally via oral gavage. Body weights and tumor measurements were collected twice weekly. Tumor width and length were measured in millimeters and converted to tumor volume (in cubic millimeters) using the formula:

$$\text{tumor volume (mm}^3\text{)} = \frac{\text{width}^2 \times \text{length}}{2}$$

Compound ID #1 demonstrated significantly superior anticancer activity when compared to either Compound ID #2 or Compound ID #3 (**FIG. 1**).

2. *Combination Screening*

Compound ID #1, Compound ID #2 and Compound ID #3 were tested in combination with the FDA approved anticancer drug Pomalyst (pomalidomide) (**FIG. 2**). Female athymic nude mice were inoculated with 5.0×10^6 MM1.S human myeloma cells suspended in a mixture of 50% Matrigel and 50% tissue culture media in a total volume of 100 μ L. Eighteen days following inoculation, the mice were pair-matched into four groups of five mice per group at an average tumor weight of 171 mm^3 per group. Group 1 (G1) was treated with vehicle only daily for 19 days. Group 2 (G2) was treated orally with pomalidomide at 10 mg/kg and intraperitoneally with dexamethasone at 0.3 mg/kg daily for 4 days per week for to Day 19. Group 3 (G3) was treated with Compound ID #1 at 100 mg/kg daily for 19 days. Group 4 (G4) was treated with Compound ID #2 at 100 mg/kg daily for 19 days. Group 5 (G5) was treated with Compound ID #3 at 100 mg/kg daily for 19 days. Group 6 (G6) was treated with Compound ID #1 at 100 mg/kg daily for 19 days plus pomalidomide/dexamethasone. Group 7 (G7) was

treated with Compound ID #2 at 100 mg/kg daily for 19 days plus pomalidomide/dexamethasone. Group 8 (G8) was treated with Compound ID #3 at 100 mg/kg daily for 19 days plus pomalidomide/dexamethasone. Vehicle and Compound ID #1, Compound ID #2 and Compound ID #3 were administered orally via oral gavage. Body weights and tumor measurements were collected twice weekly. Tumor width and length were measured in millimeters and converted to tumor volume (in cubic millimeters) using the formula:


$$tumor\ volume\ (mm^3) = \frac{width^2 \times length}{2}.$$

Compound ID #1 demonstrated significantly superior anticancer activity when combined with pomalidomide/dexamethasone compared to either Compound ID #2 or ID #3 when combined with pomalidomide/dexamethasone (**FIG. 2**).

CLAIMS

We claim:

1. A compound of formula (I):



wherein:

the group denoted by X is selected from the group consisting of: H, halo, -C₁-C₆ alkyl, aryl, -C₃-C₇ cycloalkyl, and -3-to 10-membered heterocycle, any of which may be unsubstituted or substituted with one or more of the following: -halo, -C₁-C₆ alkyl, -O-(C₁-C₆ alkyl), -OH, -CN, -COOR', -OC(O)R', NHR', N(R')₂, -NHC(O)R' or -C(O)NHR' groups wherein R' may be -H or -C₁-C₆ alkyl;

the group denoted by A is selected from the group consisting of: a bond, -C₁-C₆ alkyl, or -C₃-C₇ cycloalkyl, any of which may be unsubstituted or substituted with one or more of the following: -halo, -C₁-C₆ alkyl, -O-(C₁-C₆ alkyl), -OH, -CN, -COOR', -OC(O)R', NHR', N(R')₂, -NHC(O)R' or -C(O)NHR' groups wherein R' may be -H or -C₁-C₆ alkyl;

the group denoted by Y is selected from the group consisting of: H, -C₁-C₆ alkyl, -C₃-C₇ cycloalkyl, aryl or -3-to 10-membered heterocycle, any of which may be unsubstituted or substituted with one or more of the following: -halo, -C₁-C₆ alkyl, -O-(C₁-C₆ alkyl), -OH, -CN, -COOR', -OC(O)R', NHR', N(R')₂, -NHC(O)R' or -C(O)NHR' groups wherein R' may be -H or -C₁-C₆ alkyl; and


the group denoted by Q is selected from the group consisting of: -halo, -C₁-C₆ alkyl, -O-(C₁-C₆ alkyl), -OH, -CN, -COOR', -OC(O)R', NHR', N(R')₂, -NHC(O)R' or -C(O)NHR' groups wherein R' may be -H or -C₁-C₆ alkyl.

2. The compound of claim 1, wherein A is -C₁-C₆ alkyl.

3. The compound of claim 2, wherein Y is -C₃-C₇ cycloalkyl, aryl or -3-to 10-membered heterocycle.

4. The compound of claim 3, wherein the compound is -((1-(cyclohexylmethyl)-1H-benzo[d]imidazol-2-yl)amino)-N-hydroxybenzamide.

5. A compound of formula (II):



wherein:

the group denoted by X is selected from the group consisting of: H, halo, $-C_1-C_6$ alkyl, aryl, $-C_3-C_7$ cycloalkyl, and -3-to 10-membered heterocycle, any of which may be unsubstituted or substituted with one or more of the following: -halo, $-C_1-C_6$ alkyl, $-O-(C_1-C_6)$ alkyl, -OH, -CN, $-COOR'$, $-OC(O)R'$, NHR' , $N(R')_2$, $-NHC(O)R'$ or $-C(O)NHR'$ groups wherein R' may be -H or $-C_1-C_6$ alkyl;

the group denoted by A is selected from the group consisting of: $-C_1-C_6$ alkyl, or $-C_3-C_7$ cycloalkyl, any of which may be unsubstituted or substituted with one or more of the following: -halo, $-C_1-C_6$ alkyl, $-O-(C_1-C_6)$ alkyl, $-C_3-C_{12}$ cycloalkyl, 3 to 10-membered heterocycle, aryl, -OH, -CN, $-COOR'$, $-OC(O)R'$, NHR' , $N(R')_2$, $-NHC(O)R'$ or $-C(O)NHR'$ groups wherein R' may be -H or $-C_1-C_6$ alkyl; and

the group denoted by Q is selected from the group consisting of: -halo, $-C_1-C_6$ alkyl, $-O-(C_1-C_6)$ alkyl, -OH, -CN, $-COOR'$, $-OC(O)R'$, NHR' , $N(R')_2$, $-NHC(O)R'$ or $-C(O)NHR'$ groups wherein R' may be -H or $-C_1-C_6$ alkyl.


6. The compound of claim 5, wherein A is $-C_1-C_6$ alkyl.

7. The compound of claim 6, wherein A is substituted with $-C_3-C_{12}$ cycloalkyl, 3 to 10-membered heterocycle, or aryl.


8. The compound of claim 7, wherein the compound is -((1-(cyclohexylmethyl)-1H-benzo[d]imidazol-2-yl)amino)-N-hydroxybenzamide.

9. The compound of claim 1 or claim 5, wherein the compound is selected from the group consisting of:


4-((1-(cyclohexylmethyl)-1H-benzo[d]imidazol-2-yl)amino)-N-hydroxybenzamide ID# 1




4-((1-cyclohexyl-1H-benzo[d]imidazol-2-yl)amino)-N-hydroxybenzamide ID# 2




4-((1-cycloheptyl-1H-benzo[d]imidazol-2-yl)amino)-N-hydroxybenzamide ID# 3




4-((1-((1-fluorocyclohexyl)methyl)-1H-benzo[d]imidazol-2-yl)amino)-N-hydroxybenzamide ID# 4




4-((1-(cyclopentylmethyl)-1H-benzo[d]imidazol-2-yl)amino)-N-hydroxybenzamide ID# 5




4-((1-(2-cyclopentylethyl)-1H-benzo[d]imidazol-2-yl)amino)-N-hydroxybenzamide ID# 6




4-((1-((4,4-difluorocyclohexyl)methyl)-1H-benzo[d]imidazol-2-yl)amino)-N-hydroxybenzamide ID# 7



4-((1-((4,4-difluorocyclohexyl)methyl)-5-fluoro-1H-benzo[d]imidazol-2-yl)amino)-N-hydroxybenzamide ID# 8




N-hydroxy-4-((1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-benzo[d]imidazol-2-yl)amino)benzamide ID# 9



, and

4-((5-fluoro-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-benzo[d]imidazol-2-yl)amino)-N-hydroxybenzamide ID# 10



10. A pharmaceutical composition comprising the compound of claim 1 or 5 and a pharmaceutically acceptable carrier.
11. The pharmaceutical composition of claim 10 further comprising pomalidomide.
12. The pharmaceutical composition of claim 11 further comprising dexamethasone.
13. A method of treating cancer in a subject, the method comprising administering the compound of claim 1 or 5.
14. The method of claim 13, wherein the subject is a mammal.
15. The method of claim 13, wherein the subject exhibits a predisposing factor for malignancy selected from the group consisting of: the presence of chromosomal translocations associated with a malignancy, an incidence of polyposis or Gardner's syndrome, benign monoclonal gammopathy, kinship with persons who have had or currently have a cancer or precancerous disease, and exposure to carcinogens.

16. The method of claim 15, wherein the chromosomal translation associated with a malignancy is selected from the group consisting of: Philadelphia chromosome and t(14;18).
17. A method of preventing the progression of a cell to a neoplastic, malignant or metastatic state, the method comprising administering the compound of claim 1 or 5.
18. The method of claim 17, wherein the cell has abnormal cell growth characterized by hyperplasia, metaplasia, or dysplasia.
19. The method of any one of claims 13-18, wherein the compound is administered systemically.
20. The method of any one of claims 13-18, wherein the compound is administered locally.
21. The method of any one of claims 13-20, wherein the method further comprises administering at least a second treatment modality.
22. The method of claim 21, wherein the second treatment modality is selected from the group consisting of: radiotherapy, chemotherapy, surgery, immunotherapy, cancer vaccines, radioimmunotherapy, and a pharmaceutical composition comprising an active agent with the proviso that the active agent is not a compound of claim 1 or 5.
23. The method of claim 22, wherein the second treatment modality comprises chemotherapy selected from at least one member from the group consisting of: pomalidomide and dexamethasone.
24. The method of claim 21, wherein the second treatment modality is selected from the group consisting of: a nucleic acid binding composition, an antiemetic composition, a hematopoietic colony stimulating factor, an anxiolytic agent, and an analgesic agent.
25. The method of any one of claims 21-23, wherein the second treatment modality is administered prior to the compound.

26. The method of claim 25, wherein the second treatment modality is administered a period of one or more minutes, hours, days, weeks, or months before the compound is administered.
27. The method of any one of claims 21-23, wherein the second treatment modality is administered after the compound is administered.
28. The method of claim 27, wherein the second treatment modality is administered a period of one or more minutes, hours, days, weeks, or months after the compound is administered.
29. The method of any one of claims 21-23, wherein the second treatment modality is administered concurrently with the compound.
30. The method of any one of claims 21-23, wherein the compound and the second treatment modality are administered cyclically.




FIG. 1




FIG. 2